{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:04:54Z","timestamp":1791489894726,"version":"4.3.4"},"reference-count":89,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Acute lymphoblastic leukemia (ALL) management is evolving from a generalized approach toward a precision medicine paradigm driven by molecular heterogeneity. This review highlights how genomic profiling identifies high-risk subtypes, including KMT2A-rearranged, IKZF1-plus BCR::ABL1-positive, BCR::ABL1-like, and TP53-mutant B-cell ALL, which necessitate tailored therapies. We explore novel strategies such as BH3 mimetics, menin inhibitors, pre\u2013T-cell receptor signaling blockade, and targeted immunotherapy, which show promise in relapsed\/refractory and high-risk groups. We also address emerging challenges, including therapy-induced phenotypic escape mechanisms such as lineage switch and antigen loss. The future of ALL therapy lies in integrating these biology-driven approaches to improve outcomes across all age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This review provides a roadmap for the targeted therapy era in ALL, defining high-risk molecular subtypes and their targeted vulnerabilities. It synthesizes advances in BH3 mimetics, menin inhibition, and immunotherapy, while addressing the critical challenges of treatment resistance and phenotypic escape that define the next frontier of research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0078","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:17:11Z","timestamp":1774880231000},"page":"369-379","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incorporating ALL Biology into Treatment Decisions: Next Steps toward Targeted Therapy in Adult ALL"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-8356","authenticated-orcid":false,"given":"Caner","family":"Saygin","sequence":"first","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-4288","authenticated-orcid":false,"given":"Matthew T.","family":"Witkowski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03wmf1y16","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Colorado Anschutz Medical Campus 2 Department of Pediatrics, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3572-7600","authenticated-orcid":false,"given":"Sinan","family":"Cetin","sequence":"additional","affiliation":[{"name":"1Section of Hematology\/Oncology, University of Chicago, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-4498","authenticated-orcid":false,"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00w6g5w60","id-type":"ROR","asserted-by":"publisher"}],"name":"City of Hope National Medical Center 3 Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, , Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026050503062542600_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026050503062542600_bib2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat Genet"},{"key":"2026050503062542600_bib3","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"2026050503062542600_bib4","first-page":"1","article-title":"Innovative approaches to the management of acute lymphoblastic leukemia across the age spectrum","volume":"42","author":"Curran","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026050503062542600_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jamaoncol.2025.0613","article-title":"Management of adult acute lymphoblastic leukemia: a review","volume":"11","author":"Kantarjian","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026050503062542600_bib6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"2026050503062542600_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-023-02115-4","article-title":"Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols","volume":"38","author":"Valtis","year":"2024","journal-title":"Leukemia"},{"key":"2026050503062542600_bib9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18 to 50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"2026050503062542600_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/hematology.2021000226","article-title":"Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?","volume":"2021","author":"Luskin","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2026050503062542600_bib11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","article-title":"Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia","volume":"9","author":"Luskin","year":"2025","journal-title":"Blood Adv"},{"key":"2026050503062542600_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib15","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"key":"2026050503062542600_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","article-title":"Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy","volume":"2","author":"Jeha","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026050503062542600_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-025-01350-5","article-title":"Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults","volume":"15","author":"Harris","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026050503062542600_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/2643-3230.BCD-23-0106","article-title":"Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis","volume":"5","author":"Saygin","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026050503062542600_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41568-020-00315-z","article-title":"Advances in germline predisposition to acute leukaemias and myeloid neoplasms","volume":"21","author":"Klco","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"2026050503062542600_bib20","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/ng.2803","article-title":"Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse","volume":"45","author":"Perez-Andreu","year":"2013","journal-title":"Nat Genet"},{"key":"2026050503062542600_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood-2018-07-862946","article-title":"Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics","volume":"133","author":"Qian","year":"2019","journal-title":"Blood"},{"key":"2026050503062542600_bib22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"key":"2026050503062542600_bib23","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ng.2754","article-title":"A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia","volume":"45","author":"Shah","year":"2013","journal-title":"Nat Genet"},{"key":"2026050503062542600_bib24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ccell.2018.03.021","article-title":"Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia","volume":"33","author":"Churchman","year":"2018","journal-title":"Cancer Cell"},{"key":"2026050503062542600_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ng.3253","article-title":"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia","volume":"47","author":"Noetzli","year":"2015","journal-title":"Nat Genet"},{"key":"2026050503062542600_bib26","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1038\/ncomms8553","article-title":"Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children","volume":"6","author":"Xu","year":"2015","journal-title":"Nat Commun"},{"key":"2026050503062542600_bib27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/leu.2016.277","article-title":"Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences","volume":"31","author":"Waanders","year":"2017","journal-title":"Leukemia"},{"key":"2026050503062542600_bib28","first-page":"351","article-title":"Germline loss-of-function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies","volume":"109","author":"Stubbins","year":"2024","journal-title":"Haematologica"},{"key":"2026050503062542600_bib29","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/s41375-025-02635-1","article-title":"Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants","volume":"39","author":"Stubbins","year":"2025","journal-title":"Leukemia"},{"key":"2026050503062542600_bib30","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/leu.2017.55","article-title":"Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis","volume":"31","author":"Ratnaparkhe","year":"2017","journal-title":"Leukemia"},{"key":"2026050503062542600_bib31","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026050503062542600_bib32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"2026050503062542600_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2643-3230.BCD-22-0154","article-title":"Adult low-hypodiploid acute lymphoblastic leukemia Emerges from preleukemic TP53-mutant clonal hematopoiesis","volume":"4","author":"Kim","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2026050503062542600_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-021-01068-4","article-title":"Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL","volume":"14","author":"Simonin","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026050503062542600_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2026050503062542600_bib36","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/s41375-020-01061-9","article-title":"Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome","volume":"35","author":"Barnea Slonim","year":"2021","journal-title":"Leukemia"},{"key":"2026050503062542600_bib37","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/bloodadvances.2019000925","article-title":"Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes","volume":"3","author":"Saygin","year":"2019","journal-title":"Blood Adv"},{"key":"2026050503062542600_bib38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"2026050503062542600_bib39","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1182\/bloodadvances.2022009212","article-title":"Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal","volume":"7","author":"Geyer","year":"2023","journal-title":"Blood Adv"},{"key":"2026050503062542600_bib40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib41","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-025-02707-2","article-title":"Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma","volume":"39","author":"Cooperrider","year":"2025","journal-title":"Leukemia"},{"key":"2026050503062542600_bib42","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2026050503062542600_bib43","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"P\u00f6l\u00f6nen","year":"2024","journal-title":"Nature"},{"key":"2026050503062542600_bib44","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026050503062542600_bib45","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"key":"2026050503062542600_bib46","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib47","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050503062542600_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","article-title":"Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab","volume":"18","author":"Short","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026050503062542600_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"key":"2026050503062542600_bib50","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.clml.2025.05.013","article-title":"A phase I\/II trial of ruxolitinib with chemotherapy for patients with relapsed and\/or refractory Philadelphia-like acute lymphoblastic leukemia","volume":"25","author":"Goulart","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026050503062542600_bib51","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1038\/s41467-022-33143-w","article-title":"Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat Commun"},{"key":"2026050503062542600_bib52","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3324\/haematol.2023.283148","article-title":"TCF3::HLF acute lymphoblastic leukemia: still challenging to cure thirty years later","volume":"108","author":"Tasian","year":"2023","journal-title":"Haematologica"},{"key":"2026050503062542600_bib53","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/bloodadvances.2023011582","article-title":"Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+\/preBCR+ ALL","volume":"8","author":"Gentile","year":"2024","journal-title":"Blood Adv"},{"key":"2026050503062542600_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1877-1173(10)92006-1","article-title":"Early T cell differentiation lessons from T-cell acute lymphoblastic leukemia","volume":"92","author":"Tremblay","year":"2010","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2026050503062542600_bib55","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1158\/1078-0432.CCR-23-0415","article-title":"Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia","volume":"29","author":"Saygin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026050503062542600_bib56","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","article-title":"Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia","volume":"2","author":"Gocho","year":"2021","journal-title":"Nat Cancer"},{"key":"2026050503062542600_bib57","doi-asserted-by":"crossref","first-page":"e29724","DOI":"10.1002\/pbc.29724","article-title":"Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia","volume":"69","author":"He","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2026050503062542600_bib58","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib59","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026050503062542600_bib60","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026050503062542600_bib61","first-page":"1105","article-title":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"110","author":"Aldoss","year":"2025","journal-title":"Haematologica"},{"key":"2026050503062542600_bib62","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3324\/haematol.2020.247973","article-title":"Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"key":"2026050503062542600_bib63","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","article-title":"A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Short","year":"2024","journal-title":"Blood Adv"},{"key":"2026050503062542600_bib64","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"key":"2026050503062542600_bib65","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41375-024-02414-4","article-title":"Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"38","author":"Ravandi","year":"2024","journal-title":"Leukemia"},{"key":"2026050503062542600_bib66","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"2026050503062542600_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/bloodadvances.2025016565","article-title":"Mini-hyper-CVD plus venetoclax and navitoclax for relapsed\/refractory acute lymphoblastic leukemia","volume":"10","author":"Short","year":"2026","journal-title":"Blood Adv"},{"key":"2026050503062542600_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The MCL1-specific inhibitor S63845 acts synergistically with venetoclax\/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"2026050503062542600_bib69","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in high-risk B-ALL","volume":"4","author":"Moujalled","year":"2020","journal-title":"Blood Adv"},{"key":"2026050503062542600_bib70","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41417-022-00511-z","article-title":"The combination of ruxolitinib and Bcl-2\/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion","volume":"29","author":"Mayumi","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"2026050503062542600_bib71","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","article-title":"A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed\/refractory hematologic malignancies","volume":"30","author":"Desai","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026050503062542600_bib72","doi-asserted-by":"crossref","first-page":"107924","DOI":"10.1016\/j.leukres.2025.107924","article-title":"Menin inhibitors in KMT2A-rearranged leukemia: mechanistic insights, clinical trial progress, and potential of combination therapies","volume":"157","author":"Yang","year":"2025","journal-title":"Leuk Res"},{"key":"2026050503062542600_bib73","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"2026050503062542600_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050503062542600_bib75","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026050503062542600_bib76","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"2026050503062542600_bib77","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41375-024-02312-9","article-title":"Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations","volume":"38","author":"Miao","year":"2024","journal-title":"Leukemia"},{"key":"2026050503062542600_bib78","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"key":"2026050503062542600_bib79","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1182\/bloodadvances.2025015881","article-title":"Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry","volume":"9","author":"John","year":"2025","journal-title":"Blood Adv"},{"key":"2026050503062542600_bib80","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026050503062542600_bib81","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib82","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050503062542600_bib83","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"key":"2026050503062542600_bib84","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1038\/bcj.2017.89","article-title":"Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A\/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis","volume":"7","author":"Haddox","year":"2017","journal-title":"Blood Cancer J"},{"key":"2026050503062542600_bib85","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23266","article-title":"Lineage switch in childhood acute leukemia: an unusual event with poor outcome","volume":"87","author":"Rossi","year":"2012","journal-title":"Am J Hematol"},{"key":"2026050503062542600_bib86","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.3324\/haematol.2023.283566","article-title":"Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed\/refractory T-cell acute lymphoblastic leukemia","volume":"108","author":"Aldoss","year":"2023","journal-title":"Haematologica"},{"key":"2026050503062542600_bib87","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"key":"2026050503062542600_bib88","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"2026050503062542600_bib89","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2013.354","article-title":"CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage","volume":"28","author":"Slamova","year":"2014","journal-title":"Leukemia"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0078\/3755516\/bcd-25-0078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/369\/3783091\/bcd-25-0078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/369\/3783091\/bcd-25-0078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:06:39Z","timestamp":1777964799000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/3\/369\/784440\/Incorporating-ALL-Biology-into-Treatment-Decisions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":89,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0078","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}